. Author manuscript; available in PMC: 2014 May 13.

Published in final edited form as: Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 May 3;116(1):e37–e51. doi: 10.1016/j.oooo.2013.02.017

Table II.

Overview of the competitive landscape: current and emerging solutions to address radiation-induced xerostomia in H&N cancer patients

Type of solution	Type of treatment	Existing solutions	Emerging solutions
Prevention		Intensity-modulated RT Intensity-modulated proton RT Salivary gland transfer Radioprotective drugs (amifostine)	Radioprotective drugs (tempol)
Treatment	Palliation	Use of water Saliva substitutes, gels Hydration pack device
Treatment	Stimulation	Cholinergic muscarinic receptor agonist drugs Chewing-gum and bitter substances Acupuncture	Electrical stimulation devices Gene therapy Growth factors BoNT
Treatment	Regeneration		Stem cell transfer Artificial glands

The solutions as classified according to their goal—prevention or treatment of xerostomia—as well as their stage in the clinical use—existing solutions in the clinics versus emerging solution, still under preclinical or clinical research investigation.